Archives

  • 2018-07
  • 2018-10
  • 2018-11
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2019-12
  • 2020-01
  • 2020-02
  • 2020-03
  • 2020-04
  • 2020-05
  • 2020-06
  • 2020-07
  • 2020-08
  • 2020-09
  • 2020-10
  • 2020-11
  • 2020-12
  • 2021-01
  • 2021-02
  • 2021-03
  • 2021-04
  • 2021-05
  • 2021-06
  • 2021-07
  • 2021-08
  • 2021-09
  • 2021-10
  • 2021-11
  • 2021-12
  • 2022-01
  • 2022-02
  • 2022-03
  • 2022-04
  • 2022-05
  • 2022-06
  • 2022-07
  • 2022-08
  • 2022-09
  • 2022-10
  • 2022-11
  • 2022-12
  • 2023-01
  • 2023-02
  • 2023-03
  • 2023-04
  • 2023-05
  • 2023-06
  • 2023-07
  • 2023-08
  • 2023-09
  • 2023-10
  • 2023-11
  • 2023-12
  • 2024-01
  • 2024-02
  • 2024-03
  • In Taiwan the crude incidence rate

    2019-05-10

    In Taiwan, the crude incidence rate of colorectal cancer among male and female populations increased from 49.98 to 69.90, and 39.48 to 51.36 per 100,000 people, respectively, during the price between 2006 and 2011. The observed 2-year survival rates of colon cancer in 2004–2006, 2007–2009 and 2010–2011 were 72.92, 73.05 and 74.22, respectively. Furthermore, the observed 5-year survival rate of colon cancer was 55.92 in 2004–2006, and 55.59 in 2007–2009. Albeit the observed survival rate did not increase significantly during the surveyed periods, the number of CRC survivors will increase because of the increasing incidence rate and the potential improvement of cancer treatments in the future. This population might draw considerable attention in the treatment of cancer, general health care and rehabilitation. Based on the results that emerged from the current research, the benefits of exercise and general participation in physical activity should be clearly stated to the patients. Physicians should consider counseling CRC survivors to adopt a physically active lifestyle, recommending that they be more active and remain active, and incorporate physical activity into their daily routines.
    Conclusions
    Conflict of interest
    Introduction Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. More than 75% of HCC cases occur in the Far East and Southeast Asia. Only a small proportion of patients have their HCC detected in an early curable stage, thus the worldwide 5-year survival rate of HCC only slightly increased from 5 to 15% over the past two decades. The major causes of unsatisfactory prognosis of HCC include degree of liver function impairment and heterogeneous nature of HCC, which affect treatment outcome. Cumulative evidence also suggests that accurate assessment and staging of HCC, and correct designation of optimal treatments may prolong survival rate of HCC. Among current HCC staging systems, the Barcelona Clinic Liver Cancer (BCLC) classification is the one of most reliable for prognosis prediction at the time of HCC diagnosis. To be categorized as BCLC intermediate-stage, patients are asymptomatic (performance status score, 0) with multinodular tumors but without vascular invasion or extrahepatic spread. The median survival time was 16 months for patients with BCLC intermediate-stage HCC. Based on the AASLD guideline, a revised version of the Barcelona Clinic Liver Cancer (BCLC) staging system by the American Association for the Study of Liver Diseases (AASLD), transarterial chemoembolization (TACE) has been recognized as an effective option for those with intermediate stage HCC. Although TACE has been considered a palliative treatment for unresectable HCC, previous meta-analyses indicated glycolysis treatment with TACE is associated with a significantly higher 2-year survival rate than those patients receiving conservative management or suboptimal therapies. Nonetheless, the improvement in long-term survival is not clear. In addition, TACE-associated adverse events include post-embolization syndrome, relevant liver function deterioration, ascites and gastrointestinal bleeding; such adverse events are not unusual. Because intermediate stage HCC includes both Child-Turcotte-Pugh (CTP) class A and B patients, ascertaining the optimal treatments for these patients still remains a substantial challenge. Recent advances in liver surgery make the resection of intermediate stage HCC possible. It is therefore important to clarify the optimal and effective therapy for intermediate stage HCC patients. The purpose of our study was to compare the long-term survival of intermediate stage HCC patients treated with surgical resection or TACE.
    Materials and methods
    Discussion According to the BCLC staging system and recommended treatment strategy (AASLD guideline), TACE has been recognized as an effective treatment option for those with intermediate stage HCC. Cumulative meta-analysis of published randomized controlled trials further indicates that patient survival is significantly improved after TACE. However, the 1-year mortality of intermediate stage HCC patients receiving TACE still remains unsatisfactory. It would appear that TACE may not be the optimal therapy for all intermediate stage HCC patients.